Lesson plan

TACT908

TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches. It is a positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring. The drug acts as a serotonin 5-HT 1B and 5-HT 2A receptor agonist. Its at the serotonin 5-HT 2A receptor is 52 nM ( ≈ 30% of that of serotonin) and its at the serotonin 5-HT 1B receptor is 143 nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT 2A receptor agonist. It showed little or no activity at 45 other screened targets, including the serotonin 5-HT 1A , 5-HT 2B , and 5-HT 3 receptors as well as the monoamine transporters (MATs). Other serotonin receptors besides the preceding, such as the serotonin 5-HT 2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) ( = 7,252 nM). TACT908 is under development by Tactogen. It was patented by Matthew Baggott of Tactogen in 2023. As of January 2025, the drug is in preclinical research for cluster headaches.…

Back to article

Article summary

TACT908, also known as [2-(indolizin-1-yl)ethyl]dimethylamine (2ZEDMA), is a serotonin receptor agonist of the indolizinylethylamine family which is under development for the treatment of cluster headaches. It is a positional isomer of the tryptamine serotonergic psychedelic N,N-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring. The drug acts as a serotonin 5-HT 1B and 5-HT 2A receptor agonist. Its at the serotonin 5-HT 2A receptor is 52 nM ( ≈ 30% of that of serotonin) and its at the serotonin 5-HT 1B receptor is 143 nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT 2A receptor agonist. It showed little or no activity at 45 other screened targets, including the serotonin 5-HT 1A , 5-HT 2B , and 5-HT 3 receptors as well as the monoamine transporters (MATs). Other serotonin receptors besides the preceding, such as the serotonin 5-HT 2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A (MAO-A) ( = 7,252 nM). TACT908 is under development by Tactogen. It was patented by Matthew Baggott of Tactogen in 2023. As of January 2025, the drug is in preclinical research for cluster headaches.…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.